Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.

a, b and c denote oligo-barcodes modified with red and green colours by biotin-dUTP and digoxigenin-dUTP antibodies respectively. Based on the mapping results of cytogenetic markers, we illustrated ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...

Jobs in one particular industry are projected to grow much faster than the average of all occupations, according to the ...

The European Medicines Agency (EMA) has given a positive recommendation for Rytelo ( imetelstat) for the treatment of adult ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Advances in molecular testing, such as cytogenetic analysis of plasma cells, have allowed clinicians to stratify patients based on risk, and tailor therapy accordingly. Importantly, the focus on ...

After months of covert surveillance, authorities launched five operations to seize an unprecedented 100 kilograms of depleted ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...